China Biologic Products Inc. (NASDAQ:CBPO) shares rose 2.2% on Monday . The stock traded as high as $114.09 and last traded at $113.03, with a volume of 90,457 shares. The stock had previously closed at $110.64.

CBPO has been the subject of several recent analyst reports. Jefferies Group restated a “buy” rating and issued a $136.00 price target on shares of China Biologic Products in a research note on Friday. Zacks Investment Research upgraded China Biologic Products from a “hold” rating to a “buy” rating and set a $134.00 price target for the company in a research note on Wednesday, April 27th. Finally, Credit Suisse Group AG upgraded China Biologic Products from a “neutral” rating to an “outperform” rating in a research note on Tuesday, July 5th.

The company’s 50-day moving average price is $110.59 and its 200-day moving average price is $116.00. The stock has a market capitalization of $3.01 billion and a PE ratio of 33.84.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.06. The company had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $74 million. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. Analysts predict that China Biologic Products Inc. will post $4.29 earnings per share for the current fiscal year.

In other news, CFO Ming Yang sold 13,908 shares of the company’s stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $113.64, for a total transaction of $1,580,505.12. Following the completion of the transaction, the chief financial officer now directly owns 52,282 shares of the company’s stock, valued at approximately $5,941,326.48. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Ming Yin sold 19,618 shares of the company’s stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $113.64, for a total value of $2,229,389.52. Following the transaction, the vice president now directly owns 51,419 shares of the company’s stock, valued at $5,843,255.16. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have added to or reduced their stakes in the company. Russell Frank Co boosted its position in China Biologic Products by 69.1% in the fourth quarter. Russell Frank Co now owns 14,104 shares of the biopharmaceutical company’s stock valued at $1,993,000 after buying an additional 5,764 shares in the last quarter. Employees Retirement System of Texas purchased a new stake in shares of China Biologic Products during the fourth quarter worth about $2,846,000. Finally, WCM Investment Management CA boosted its stake in shares of China Biologic Products by 22.8% in the fourth quarter. WCM Investment Management CA now owns 60,753 shares of the biopharmaceutical company’s stock worth $8,655,000 after buying an additional 11,282 shares during the period.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.